Market Research Reports, Inc. has announced the addition of “EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023” research report to their offering. See more at- http://mrr.cm/ZmN
2. www.MarketResearchReports.com
Introduction to Report
Launch Date: July 7, 2014
Number of Pages: 107
Geography Coverage: Global
Available Format: PDF
Price For Single User License: USD 3,995
Price For Site License: USD 7,990
Price For Global User License: USD 11,985
Delivery Time: Within 24 Hours (During Working
Days)
3. www.MarketResearchReports.com
About the Report
Acute coronary syndrome (ACS) is a serious
cardiovascular disease associated with high
healthcare costs, frequent recurrences and
hospitalizations, and high risks of sudden death
and short-term mortality.
The ACS incidence increases with age and will be
a significant public health problem as the elderly
population increases around the world.
ACS is classified into three disease entities based
on evidence of heart muscle damage inferred from
a person’s symptoms, changes in the ST-tracing of
the electrocardiogram (ECG), and levels of cardiac
biomarkers that signify heart muscle death: ST-
elevation myocardial infarction (STEMI), non-ST-
elevation myocardial infarction (NSTEMI), and
unstable angina (UA).
4. www.MarketResearchReports.com
Scope:
The ACS EpiCast Report provides an overview of
the ACS risk factors and comorbidities, a
discussion of the ACS global and historical trends,
and a 10-year epidemiological patient forecast for
ACS from 2013 to 2023 in the seven major markets
(7MM) (US, France, Germany, Italy, Spain, UK, and
Japan).
Hospitalized incident cases of ACS, segmented
by STEMI, NSTEMI, and UA
ACS cases that survived until hospital discharge,
segmented by STEMI, NSTEMI, and UA
ACS cases that survived for one year post-
hospital discharge, segmented by STEMI, NSTEMI,
and UA
5. www.MarketResearchReports.com
Scope: Continues…
Diagnosed prevalent cases of myocardial
infarction (MI) segmented by STEMI and NSTEMI
from 2013 to 2023 in the six major markets (6MM)
(US, France, Germany, Italy, Spain, and UK)
The ACS epidemiology report is written and
developed by Masters- and PhD-level
epidemiologists.
The EpiCast Report is in-depth, high quality,
transparent and market-driven, providing expert
analysis of disease trends in the 7MM.
6. www.MarketResearchReports.com
Reasons to buy:
Develop business strategies by understanding
the trends shaping and driving the global ACS
market.
Quantify patient populations in the global ACS
market to improve product design, pricing, and
launch plans.
Organize sales and marketing efforts by
identifying the patient segmentations that present
the best opportunities for ACS therapeutics in
each of the markets covered.
Identify the number of ACS cases survived to key
time periods.
7. www.MarketResearchReports.com
Report Coverage
1. Introduction
2. Epidemiology
3. Strengths of the Analysis
4. Appendix
For more details regarding Report coverage see the last slide
All logos and Images mentioned on this slide belong to their respective owners.
8. www.MarketResearchReports.com
Custom Research:
Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let
us know your specific research requirements. Our goal
is to cater to your requirements be it for a custom
market research project, syndicated research report on
a specific market or industry sector, newsletter creation,
case study development or anything else related to
marketing research.
For Any Customization Related query Visit IdeaCenter @
http://www.marketresearchreports.com/idea-center
9. www.MarketResearchReports.com
How To Buy This Report?
Visit following URL to see Table of Content and
purchase this publication:
http://mrr.cm/ZmN
About Market Research Reports, Inc.
Market Research Reports provides a customized set
of reports from reputed Publishers, built on the
intelligence available within organizations and
leverages on our motto of “Intelligence Redefined”.
Contact : Amitava Sen
Email : info@marketresearchreports.com
Phone: +1 302-703-7787 (USA) +91-8762746600 (India)